CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma

Biochemical and Biophysical Research Communications

Volumn 317, Issue 3, 2004, Pages 837-843

  Duxbury, Mark S ^a   Ito, Hiromichi ^a   Ashley, Stanley W ^a   Whang, Edward E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Cancer; Carcinoembryonic antigen related cell adhesion molecule 6; Immunotherapy; Pancreatic

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CASPASE; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BY114; RIBOSOME INACTIVATING PROTEIN; SAPORIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG TARGETING; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA; ANTIGENS, CD; ANTIGENS, NEOPLASM; CASPASE 3; CASPASES; CELL ADHESION MOLECULES; CELL LINE, TUMOR; HUMANS; PANCREATIC NEOPLASMS;

MUS MUSCULUS;

EID: 1842740116     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.03.128     Document Type: Article

References (29)

1. Jantscheff P., Terracciano L., Lowy A., Glatz-Krieger K., Grunert F., Micheel B., Brummer J., Laffer U., Metzger U., Herrmann R., Rochlitz C. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J. Clin. Oncol. 21:2003;3638-3646.
2. Kakudo K., Takami H., Katayama S., Matsuura N., Kamoshida S., Miyauchi A., Watanabe K. Carcinoembryonic antigen and nonspecific cross-reacting antigen in medullary carcinoma of the thyroid. Acta Pathol. Jpn. 40:1990;261-266.
3. Kodera Y., Isobe K., Yamauchi M., Satta T., Hasegawa T., Oikawa S., Kondoh K., Akiyama S., Itoh K., Nakashima I. Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation. Br. J. Cancer. 68:1993;130-136.
4. Kuroki M., Yamanaka T., Matsuo Y., Ohtani T., Matsuo Y., Minowada J., Misumi Y., Oikawa S., Nakazato H., Matsuoka Y. Characterization of a species of non-specific cross-reacting antigen (NCA) expressed by human monocytic cell lines: structure and expression during cell differentiation. Int. J. Cancer. 56:1994;886-891.
5. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., Whang E.E. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene. 23:2004;465-473.
6. Kreitman R.J. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11:1999;570-578.
7. Fodstad O., Kvalheim G., Pihl A., Godal A., Funderud S. New indirect approach to the therapeutic use of immunotoxins. J. Natl. Cancer Inst. 80:1988;439-443.
8. Weltman J.K., Pedroso P., Johnson S.A., Davignon D., Fast L.D., Leone L.A. Rapid screening with indirect immunotoxin for monoclonal antibodies against human small cell lung cancer. Cancer Res. 47:1987;5552-5556.
9. Endo Y., Tsurugi K., Lambert J.M. The site of action of six different ribosome-inactivating proteins from plants on eukaryotic ribosomes: the RNA N-glycosidase activity of the proteins. Biochem. Biophys. Res. Commun. 150:1988;1032-1036.
10. Bergamaschi G., Perfetti V., Tonon L., Novella A., Lucotti C., Danova M., Glennie M.J., Merlini G., Cazzola M. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br. J. Haematol. 93:1996;789-794.
11. Barbieri L., Battelli M.G., Stirpe F. Ribosome-inactivating proteins from plants. Biochim. Biophys. Acta. 1154:1993;237-282.
12. Mayne K.M., Pulford K., Jones M., Micklem K., Nagel G., van der Schoot C.E., Mason D.Y. Antibody By114 is selective for the 90 kD PI-linked component of the CD66 antigen: a new reagent for the study of paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 83:1993;30-38.
13. Tooze J.A., Saso R., Marsh J.C., Papadopoulos A., Pulford K., Gordon-Smith E.C. The novel monoclonal antibody By114 helps detect the early emergence of a paroxysmal nocturnal hemoglobinuria clone in aplastic anemia. Exp. Hematol. 23:1995;1484-1491.
14. Kasahara K., Watanabe K., Takeuchi K., Kaneko H., Oohira A., Yamamoto T., Sanai Y. Involvement of gangliosides in glycosylphosphatidylinositol-anchored neuronal cell adhesion molecule TAG-1 signaling in lipid rafts. J. Biol. Chem. 275:2000;34701-34709.
15. Raitano A.B., Scuderi P., Korc M. Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas. 5:1990;267-277.
16. Gardner-Thorpe J., Ito H., Ashley S.W., Whang E.E. Differential display of expressed genes in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 293:2002;391-395.
17. Kawakami M., Kawakami K., Puri R.K. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J. Neurooncol. 65:2003;15-25.
18. Weber F.W., Floeth F., Asher A., Bucholz R., Berger M., Prados M., Chang S., Bruce J., Hall W., Rainov N.G., Westphal M., Warnick R.E., Rand R.W., Rommell F., Pan H., Hingorani V.N., Puri R.K. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. Suppl. 88:2003;93-103.
19. Schnell R., Borchmann P., Staak J.O., Schindler J., Ghetie V., Vitetta E.S., Engert A. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann. Oncol. 14:2003;729-736.
20. Posey J.A., Khazaeli M.B., Bookman M.A., Nowrouzi A., Grizzle W.E., Thornton J., Carey D.E., Lorenz J.M., Sing A.P., Siegall C.B., LoBuglio A.F., Saleh M.N. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin. Cancer Res. 8:2002;3092-3099.
21. Hall W.A. Targeted toxin therapy for malignant astrocytoma. Neurosurgery. 46:2000;544-551.
22. Schnell R., Vitetta E., Schindler J., Borchmann P., Barth S., Ghetie V., Hell K., Drillich S., Diehl V., Engert A. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia. 14:2000;129-135.
23. Winkler U., Barth S., Schnell R., Diehl V., Engert A. The emerging role of immunotoxins in leukemia and lymphoma. Ann. Oncol. 8(Suppl. 1):1997;139-146.
24. LoBuglio A.F., Saleh M.N. Monoclonal antibody therapy of cancer. Crit Rev. Oncol. Hematol. 13:1992;271-282.
25. Flavell D.J., Boehm D.A., Noss A., Warnes S.L., Flavell S.U. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br. J. Cancer. 84:2001;571-578.
26. Stong R.C., Uckun F., Youle R.J., Kersey J.H., Vallera D.A. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood. 66:1985;627-635.
27. Bolognesi A., Polito L., Tazzari P.L., Lemoli R.M., Lubelli C., Fogli M., Boon L., de Boer M., Stirpe F. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br. J. Haematol. 110:2000;351-361.
28. Komatsu N., Oda T., Muramatsu T. Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and Pseudomonas toxin. J. Biochem. (Tokyo). 124:1998;1038-1044.
29. Keppler-Hafkemeyer A., Kreitman R.J., Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int. J. Cancer. 87:2000;86-94.